The UK cold drug logistics market is forecast to grow steadily from USD 2,450 Million in 2020 to USD 5,860 Million by 2035, supported by digitalization, innovation, rising healthcare expenditure, and rigorous demand for vaccine and biologics distribution. CAGR is estimated at 5.7% over 2025–2035, with key gains post-pandemic and further industry professionalization in the next decade.

Read More - https://bussinessinsights.com/research-report/uk-cold-drug-logistics

Vaccines lead the application segment in 2025, reflecting sustained COVID-19 and influenza immunization initiatives. Biopharmaceuticals are the second-largest segment, fueled by growth in personalized and advanced therapies. Clinical trial material handling is also sizable, as pharmaceutical R&D pipelines broaden across the UK.

Request Free Sample- https://bussinessinsights.com/request/logistics/uk-cold-drug-logistics

Frequently Asked Questions

Who are the key players in UK Cold Drug Logistics industry?
The top five players in the UK Cold Drug Logistics industry include DHL Supply Chain, Kuehne + Nagel, UPS Healthcare, Movianto, and Alloga UK. These companies provide advanced temperature-controlled transportation and warehousing solutions, ensuring pharmaceutical integrity and regulatory compliance across the cold chain logistics sector.

What is the UK Cold Drug Logistics growth?
The UK Cold Drug Logistics sector has experienced substantial growth, driven by increased demand for temperature-sensitive biopharmaceuticals. In 2023, DHL Supply Chain expanded its cold chain fleet in the UK, reflecting rising investments and a growing market, estimated to witness a CAGR of over 7% through 2027.

Which segment accounted for the largest UK Cold Drug Logistics share?
Pharmaceuticals accounted for the largest share in the UK Cold Drug Logistics market. The segment includes vaccines, biologics, and specialty drugs, which require strict temperature control. The COVID-19 pandemic notably boosted this segment, driving cold chain demand for secure and timely delivery of critical medicines.

Thanks & Regards,
Manisha C
sales@bussinessinsights.com